Trial Profile
PRIMIER:Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI-724 as First Line Treatment for Metastatic Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Foscenvivint (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms PRIMIER
- 13 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to Study drug supply issues.
- 24 Sep 2015 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018 as reported by ClinicalTrials.gov.
- 24 Sep 2015 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov.